Herbal medicine for viral hepatitis

Alternative and Complementary Therapies

Volumn 16, Issue 3, 2010, Pages 151-157

  Yarnell, Eric ^a   Abascal, Kathy ^b  

^a Northwest Naturopathic Urology   (United States)

^b Botanical Medicine Academy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953925829     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/act.2010.16308     Document Type: Article

References (42)

1. Kliger B, Ulbricht C, Basch E, et al. Andrographis paniculata for the treatment of upper respiratory infection: A systematic review by the Natural Standard Research Collaboration. Explore 2006;2:25-29.
2. Chturvedi GN, Tomar GS, Tiwari SK, Singh KP. Clinical studies on kalmegh (Andrographis paniculata Nees) in infective hepatitis. J Int Institute Ayurveda 1983;2:208-211.
3. Deng WL. Outline of current clinical and pharmacological research on Andrographis paniculata in China [in Chinese]. Newsletters of Chinese Herbal Med 1978;10:27-31.
4. El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine 2009;16:391-400.
5. Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres [in German]. Med Klin 1978;73(28-29):1060-1065.
6. Baijal R, Patel N, Kohlapure SA. Evaluation of efficacy and safety of Liv.52 DS tablets in acute viral hepatitis: A prospective, double-blind, randomized, placebo-controlled, phase III clinical trial. Medicine Update 2004;12: 41-53.
7. Habibullah CM, Chandra V, Padmanaban CG, Ramakrishna R. Liv.52 in acute viral hepatitis-results of a double blind study. Antiseptic 1971;75:491.
8. Sama SK, Krishnamurthy L, Ramachandran K, Lal K. Efficacy of an indigenous compound preparation (Liv-52) in acute viral hepatitis-a double blind study. Ind J Med Res 1976;64:738-742.
9. Liu C, Tseng A, Yang S. Chinese Herbal Medicine: Modern Application of Traditional Formulas. Boca Raton, FL: CRC Press, 2005.
10. Yarnell E. Natural Approach to Gastroenterology, 2nd ed. Wenatchee, WA: Healing Mountain Publishing, 2010:in press.
11. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008;359:2429-2441.
12. Orlent H, Hansen BE, Willems M, et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. J Hepatol 2006;45:539-546.
13. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin (stronger neo-minophagen C [SNMC]) for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002;62(suppl1):94-100.
14. Ikeda K, Arase Y, Kobayashi M, et al. A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferonresistant active chronic hepatitis C: A cohort study of 1249 patients. Dig Dis Sci 2006;51:603-609.
15. Veldt BJ, Hansen BE, Ikeda K, et al. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 2006;41:1087-1094.
16. Tsubota A, Kumada H, Arase Y, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: A randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol 1999;11:1077-1083.
17. Anand AC, Seth AK, Nagpal A, et al. Initial experience with ribavirin plus glycyrrhizin in renal allograft recipients with chronic hepatitis C. Indian J Gastroenterol 2004;23:226-227.
18. Sumida Y, Kanemasa K, Fukumoto K, et al. Utility of a little phlebotomy intermittently just before intravenous injection of glycyrrhizin for patients with chronic hepatitis C [in Japanese]. Nippon Shokakibyo Gakkai Zasshi 2007;104:1044-1050.
19. Kato J, Miyanishi K, Kobune M, et al. Long-term phlebotomy with lowiron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007;42:830-836.
20. Van Rossum TGJ, Vulto AG, De Man RA, et al. Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 1998;12:199-205.
21. Shintani S, Murase H, Tsukagoshi H, Shiigai T. Glycyrrhizin (licorice)- induced hypokalemic myopathy: Report of 2 cases and review of the literature. Eur Neurol 1992;32:44-51.
22. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: Results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998;28:615-621.
23. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007;4:CD003620.
24. Sene D, Limal N, Cacoub P. Hepatitis C virus-associated extrahepatic manifestations: A review. Metabolic Brain Dis 2004;19(3/4):357-381.
25. Abascal K, Yarnell E. Increasing vitality with adaptogens: Multifaceted herbs for treating physical and mental stress. Altern Complement Ther 2003;9:54-60.
26. Yarnell E, Abascal K. Dandelion (Taraxacum officinale and T. mongolicum). Integr Med 2009;8:35-38.
27. Quiles JL, Aguilera C, Mesa MD, et al. An ethanolic-aqueous extract of Curcuma longa decreases the susceptibility of liver microsomes and mitochondria to lipid peroxidation in atherosclerotic rabbits. Biofactors 1998;8:51-57.
28. Messner DJ, Sivam G, Kowdley KV. Curcumin reduces the toxic effects of iron loading in rat liver epithelial cells. Liver Int 2009;29:63-72.
29. Yarnell E, Abascal K. An herbal formula for treating intractable epilepsy: A review of the literature. Altern Complemen Ther 2000;6:203-206.
30. Hirayama C, Okumura M, Tanikawa K, et al. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis. Gastroenterol Jpn 1989;24:715-719.
31. Yamamoto S, Oka H, Kanno T, et al. Controlled prospective trial to evaluate Syosakiko-to in preventing hepatocellular carcinoma in patients with cirrhosis of the liver [in Japanese]. Gan To Kagaku Ryoho 1989;16(4pt2-2):1519- 1524.
32. Oka H, Yamamoto S, Kuroki T, et al. Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9). Cancer 1995;76: 743-749.
33. Nakagawa A, Yamaguchi T, Takao T, Amano H. Five cases of drug-induced pneumonitis due to sho-saiko-to or interferon-alpha or both. Nihon Kyobu Shikkan Gakkai Zasshi 1995;33:1361-1366.
34. Goto W, Kusumoto IT, Kadota S, et al. Suppression of hepatitis B virus surface antigen secretion by traditional plant medicines. Phytother Res 1996; 10:504-507.
35. Yu YX, Yang HQ, Zhu LZ, et al. Clinical trial of large-dose radix salviae miltorrhizae in treatment of liver fibrosis [in Chinese]. Shanghai Zhongyiyao Zazhi 1994;1:8-10.
36. Liu P, Hu YY, Liu C, et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002;8:679-685.
37. Chen YS. The efficacy of combining lamivudine with Salvia miltiorrhiza on the treatment of chronic hepatitis B liver fibrosis [in Chinese]. Redai Yixue Zazhi 2003;3:207-209.
38. Liu CH, Hu YY, Xu LM, et al. Effect of fuzheng huayu formula and its actions against liver fibrosis. Chin Med 2009;4:12.
39. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139-143
40. Suzuki H, Ohta Y, Takino T, et al. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis: Double blind trial. Asian Med J 1983;26:423-438.
41. Zhang LX, Wang BE; Coordinating Group of SNMC Trial's Society of Hepatology in China. Randomized clinical trial with two doses (100 and 40 mL) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B. Hepatol Res 2002;24:220-227.
42. Li W, Dai QT, Liu ZE. Preliminary study on early fibrosis of chronic hepatitis B treated with Ginkgo biloba composita [in Chinese]. Chung Kuo Chung His I Chieh Ho Tsa Chih 1995;15:593-595.